摘要
目的探讨伊立替康联合奈达铂治疗宫颈癌的疗效及对患者血清肿瘤标志物的影响。方法依据治疗方式的不同将102例宫颈癌患者分为观察组和对照组,每组51例,对照组患者给予多西他赛联合奈达铂治疗,观察组患者给予伊立替康联合奈达铂治疗。比较两组患者化疗后骨髓抑制情况、化疗前后血清肿瘤标志物[癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC-Ag)、甲胎蛋白(AFP)、糖类抗原125(CA125)]水平、临床疗效和不良反应发生情况。结果观察组患者白细胞计数、中性粒细胞绝对值降低率均明显低于对照组(P﹤0.01)。化疗后,两组患者CEA、SCC-Ag、AFP、CA125水平均低于本组化疗前(P﹤0.05),且观察组患者血清SCC-Ag、CA125水平均低于对照组(P﹤0.05),但两组患者血清CEA、AFP水平无明显差异(P﹥0.05)。观察组患者的治疗总有效率为90.20%,高于对照组患者的74.51%(P﹤0.05)。两组患者恶心呕吐、腹痛腹泻、低热、肝肾损伤、心肌损伤发生率均无明显差异(P﹥0.05)。结论伊立替康联合奈达铂可有效降低宫颈癌患者的血清肿瘤标志物水平,提高治疗效果,患者耐受程度较高。
Objective To explore the efficacy of irinotecan combined with nedaplatin in the treatment of cervical cancer and its influence on the serum tumor markers of patients.Method According to different treatment methods,102 patients with cervical cancer were divided into observation group and control group,with 51 cases in each group.Patients in the control group were treated with docetaxel combined with nedaplatin,and patients in the observation group were treated with irinotecan combined with nedaplatin.The bone marrow suppression,before and after chemotherapy serum tumor markers[carcinoembryonic antigen(CEA),squamous cell carcinoma antigen(SCC-Ag),α-fetal protein(AFP),carbohydrate antigen 125(CA125)]levels,the clinical efficacy and the occurrence of adverse reactions were compared between the two groups of patients after chemotherapy.Result The reduction rates of white blood cell count and absolute value of neutrophils in the observation group were significantly lower than those in the control group(P<0.01).After chemotherapy,the levels of CEA,SCC-Ag,AFP,and CA125 in the two groups were lower than those before chemotherapy(P<0.05),and serum SCC-Ag and CA125 levels in the observation group were lower than those in the control group(P<0.05),however,there was no significant difference in serum CEA and AFP levels between the two groups(P>0.05).The total effective rate of treatment in the observation group was 90.20%,which was higher than 74.51%in the control group(P<0.05).There was no significant difference in the incidence of nausea and vomiting,abdominal pain,diarrhea,lowgrade fever,liver and kidney injury,and myocardial injury between the two groups(P>0.05).Conclusion Irinotecan combined with nedaplatin can effectively reduce the level of serum tumor markers in patients with cervical cancer,improve the therapeutic effect,and the patients have a high degree of tolerance.
作者
江瑜
宋保志
吴淼星
JIANG Yu;SONG Baozhi;WU Miaoxing(Provincial Clinical College of Fujian Medical University,Fuzhou 350001,Fujian,China;Department of Gynecology,Fujian Provincial Hospital,Fuzhou 350001,Fujian,China)
出处
《癌症进展》
2021年第19期2016-2019,共4页
Oncology Progress
关键词
伊立替康
奈达铂
宫颈癌
肿瘤标志物
临床疗效
irinotecan
nedaplatin
cervical cancer
tumor marker
clinical efficacy
